首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey
【24h】

Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey

机译:血液恶性肿瘤患者细菌性血液感染的最新流行病学和抗菌素耐药性数据:一项意大利多中心前瞻性调查

获取原文
获取原文并翻译 | 示例
           

摘要

A prospective cohort study was conducted in nine hematology wards at tertiary care centres or at university hospitals located throughout Italy from January 2009 to December 2012. All of the cases of bacterial bloodstream infection (BBSI) occurring in adult patients with hematologic malignancies were included. A total of 668 bacterial isolates were recovered in 575 BBSI episodes. Overall, the susceptibility rates of Gram-negative bacteria were 59.1% to ceftazidime, 20.1% to ciprofloxacin, 79.1% to meropenem, 85.2% to amikacin, 69.2% to gentamicin and 69.8% to piperacillin/tazobactam. Resistance to third-generation cephalosporins was found in 98/265 (36.9%) of Enterobacteriaceae isolates. Among Klebsiella pneumoniae strains, 15/43 (34.9%) were resistant to carbapenems. Of 66 Pseudomonas aeruginosa isolates, 46 (69.7%) were multidrug resistant. Overall, the susceptibility rates of Gram-positive bacteria were 97.4% to vandomycin and 94.2% to teicoplanin. Among the monomicrobial cases of BBSI, the 21-day mortality rate was significantly higher for those caused by Gram-negative bacteria compared to those caused by Gram-positive bacteria (47/278, 16.9% vs. 12/212, 5.6%; p < 0.001). Among Gram-negative bacteria, the mortality rate was significantly higher for BBSI caused by K. pneumoniae, P. aeruginosa, and Acinetobacter baumannii. Our results confirm the recently reported shift of prevalence from Gram-positive to Gram-negative bacteria as causative agents of BBSIs among patients with hematologic malignancies and highlight a worrisome increasing frequency in antimicrobial resistance among Gram-negative bacteria.
机译:从2009年1月至2012年12月,在意大利的三级医疗中心或大学医院的9个血液病房中进行了一项前瞻性队列研究。所有细菌性血流感染(BBSI)的病例都发生在患有血液系统恶性肿瘤的成年患者中。在575例BBSI发作中共回收了668株细菌。总体而言,革兰氏阴性菌对头孢他啶的敏感性为59.1%,对环丙沙星的敏感性为20.1%,对美罗培南的敏感性为79.1%,对阿米卡星的敏感性为85.2%,对庆大霉素的敏感性为69.2%,对哌拉西林/他唑巴坦的敏感性为69.8%。在98/265(36.9%)的肠杆菌科细菌分离物中发现了对第三代头孢菌素的耐药性。在肺炎克雷伯菌中,有15/43(34.9%)对碳青霉烯类有抗药性。在66株铜绿假单胞菌中,有46株(69.7%)具有多重耐药性。总体而言,革兰氏阳性菌对万古霉素的敏感性为97.4%,对替考拉宁的敏感性为94.2%。在BBSI的单微生物病例中,革兰氏阴性菌引起的21天死亡率显着高于革兰氏阳性菌引起的21天死亡率(47/278,16.9%vs. 12/212,5.6%; p <0.001)。在革兰氏阴性细菌中,由肺炎克雷伯菌,铜绿假单胞菌和鲍曼不动杆菌引起的BBSI的死亡率明显更高。我们的结果证实了最近报道的血液恶性肿瘤患者中作为BBSIs病原体的革兰氏阳性菌向革兰氏阴性菌的转移,并突出了革兰氏阴性菌的耐药性令人担忧的增加频率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号